Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

PET Study in Multiple Sclerosis

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03787446
Recruitment Status : Recruiting
First Posted : December 25, 2018
Last Update Posted : April 22, 2019
Sponsor:
Collaborator:
Hoffmann-La Roche
Information provided by (Responsible Party):
Robert Carruthers, University of British Columbia

Brief Summary:
While both conventional and advanced MRI techniques offer important insights into MS pathophysiology, important aspects of this inflammatory disorder are undetectable with existing MRI technology. In Multiple Sclerosis (MS), there is growing interest in PET as an imaging modality that can increase the investigator's understanding of the disease processes and may add to an understanding of MS phenotype, particularly when combined with advanced MRI techniques such as myelin water imaging.

Condition or disease
Multiple Sclerosis

Detailed Description:

This is an exploratory study. PBR28 PET scan is new, promising and exploratory endpoints in MS clinical trials, making sample size estimation difficult.

A separate pre-screening consent form will be issued for the TSPO rs6971 polymorphism and eGFR blood samples, a separate pre-screening step. Eligible participants, according to their TSPO rs6971 polymorphism will be presented a separate study consent form to continue into the clinical trial.

Study Assessments include 1 PET scan, 1 MRI scan, OCT, EDSS exam, physical exam, cognitive questionnaires, etc.


Layout table for study information
Study Type : Observational
Estimated Enrollment : 9 participants
Observational Model: Cohort
Time Perspective: Cross-Sectional
Official Title: Positron Emission Tomography (PET) Imaging Study in Relapsing-Remitting and Primary-Progressive Multiple Sclerosis (MS): Correlations With Advanced MRI in MS
Actual Study Start Date : March 26, 2019
Estimated Primary Completion Date : March 2020
Estimated Study Completion Date : September 2020

Resource links provided by the National Library of Medicine


Group/Cohort
Multiple Sclerosis (MS) patients
3 Primary Progressive MS patients on no disease modifying therapy and 3 Relapsing-Remitting MS patients on no disease modifying therapy
Healthy Controls (HC)
3 Healthy volunteers aged between 18-60 years of age



Primary Outcome Measures :
  1. Whole Brain PBR28 binding [ Time Frame: January 2020 ]
    To show an increase in 11C-PBR28 binding in all sub-types of MS compared to healthy controls.


Secondary Outcome Measures :
  1. Myelin Water Imaging by MRI [ Time Frame: January 2020 ]
    To quantitatively measure the brain levels of water located within myelin

  2. Optical Coherence Tomography [ Time Frame: January 2020 ]
    To correlate brain levels of inflammation measured by 11C-PBR28 with Retinal Nerve Fiber Layer (RNFL) thickness on Optical Coherence Tomography (OCT).

  3. MS Spectroscopy [ Time Frame: January 2020 ]
    To correlate brain levels of inflammation and myelin measured by PET with cognitive dysfunction in MS patients.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 60 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Sampling Method:   Probability Sample
Study Population
3 untreated RRMS, 3 untreated PPMS and 3 healthy controls
Criteria

Inclusion Criteria:

  • Subjects diagnosed with Multiple Sclerosis according to the 2010 McDonald criteria or otherwise in the opinion of the investigator (including relapsing-remitting and primary-progressive).
  • Aged 18 to 60 years.
  • Mixed affinity binder according to rs6971 TSPO polymorphism1.
  • Creatinine clearance over 60 mL/min*). * Blood result valid up to 3 months prior to the MRI scan.

Exclusion Criteria:

  • Low and high affinity binders according to rs6971 TSPO polymorphism
  • Subject pregnant or breastfeeding.
  • Subjects with a Body Mass Index (BMI) >35kg/m³.
  • Hospitalization within 1 month of screening visit.
  • Medical history or current heart failure
  • Medical history or current pulmonary failure
  • Current or Historical Drug or alcohol abuse in the opinion of the investigator.
  • Regular use of anti-inflammatory agents (more than once a week use of aspirin, NSAIDS, Steroids, immunomodulating drugs), unless patient is able to washout from anti-inflammatory drugs 2 weeks prior to PBR PET scan.
  • Neurological disorder other than MS, including Brain Trauma, stroke, Parkinson disease, Alzheimer disease, encephalitis.
  • Subjects with a history of radiation treatment or other high amounts of radiation exposure in the opinion of the investigator.
  • Subjects with a history of metastatic cancer including solid tumors and hematological malignancies, except basal cell, in situ squamous cell carcinoma of the skin, and in situ carcinoma of the cervix or the uterus that have been excised with clear margins.
  • Inability to tolerate lying supine for the duration of the MRI and PET scan.
  • Claustrophobia.
  • Current use of MS drugs as described by the list of prohibited medications.

Exclusion specific to MRI (All MRI specific criteria is subject to conditions posed by the MRI technologist or radiologist):

  • Known or suspected piece of metal in eye(s)
  • Irremovable piercing or recent tattoos in the last 6 weeks
  • Cardiac pacemakers, wires or defibrillator
  • Artificial heart valve
  • Brain aneurysm clip
  • Electrical stimulator for nerves or bones
  • Deep brain stimulator
  • Implanted drug infusion pump
  • Coil, catheter, or filter in any blood vessel
  • Orthopedic hardware (artificial joint, plate, screws) inserted within the last 6 weeks
  • Surgery within the last 6 weeks
  • Harrington rod for scoliosis
  • Other metallic prosthesis
  • Any metal fragments, Shrapnel, bullets, or metal prosthesis
  • Irremovable dentures, braces or retainer(s)
  • IUDs containing metal
  • Previous surgery of the brain, eyes, ears, breast, chest, heart, or spine in the opinion of the investigator and MRI technician(s)

Exclusion specific to OCT:

  • Medical history of Macular degeneration
  • Degenerative and/or symptomatic Retinopathy
  • Medical history of Glaucoma
  • Medical history of Amblyopia with vision loss
  • Medical history of Diabetes

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03787446


Contacts
Layout table for location contacts
Contact: Janice Jong 604-827-1892 janice.jong@ubc.ca
Contact: Erin Gallinger 604-827-1921 erin.gallinger@ubc.ca

Locations
Layout table for location information
Canada, British Columbia
UBC MS & NMO Clinical Trials Group Recruiting
Vancouver, British Columbia, Canada, V6T1Z3
Contact: Janice Jong    604-827-1892    janice.jong@ubc.ca   
Principal Investigator: Robert L Carruthers, MD, FRCPS         
Sponsors and Collaborators
University of British Columbia
Hoffmann-La Roche
Investigators
Layout table for investigator information
Principal Investigator: Robert L Carruthers, MD MS Clinical Trials Group

Layout table for additonal information
Responsible Party: Robert Carruthers, Principal Investigator, University of British Columbia
ClinicalTrials.gov Identifier: NCT03787446     History of Changes
Other Study ID Numbers: H18-02393
First Posted: December 25, 2018    Key Record Dates
Last Update Posted: April 22, 2019
Last Verified: April 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No

Additional relevant MeSH terms:
Layout table for MeSH terms
Sclerosis
Multiple Sclerosis
Multiple Sclerosis, Chronic Progressive
Pathologic Processes
Demyelinating Autoimmune Diseases, CNS
Autoimmune Diseases of the Nervous System
Nervous System Diseases
Demyelinating Diseases
Autoimmune Diseases
Immune System Diseases